Juvéderm Volift (VYC-17.5L), a Hyaluronic Acid Filler with Lidocaine, is Safe and Effective for Correcting Nasolabial Folds in Chinese Subjects

• Published in: Clinical, cosmetic and investigational dermatology Vol. 15; pp. 237 - 245
• Main Authors: Xie, Yun, Li, Qin, Gao, Zhanwei, Sun, Jiaming, Li, Dong, Harvey, Candice, Qu, Jiazhi, Snow, Sean, Li, Qingfeng
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Aesthetics; Care and treatment; Dermal fillers; Ethics; FDA approval; Females; Hyaluronic acid; Lidocaine; Original Research; Pain; Pharmaceutical industry; Ireland; China; lidocaine; dermal fillers; hyaluronic acid
• ISSN: 1178-7015; 1178-7015
• DOI: 10.2147/CCID.S344350

Hyaluronic acid injectable gels are commonly used to treat nasolabial folds (NLFs). We evaluated the safety and effectiveness of VYC-17.5L for correcting NLFs in Chinese subjects. This prospective, multicenter, double-blind, within-subject‒controlled study randomized adults with moderate-to-severe NLFs to VYC-17.5L treatment (initial and touch-up) in 1 NLF and control (without lidocaine) in the contralateral NLF. Effectiveness endpoints at 6 months included noninferiority of VYC-17.5L to control in NLF Severity Scale response rate (primary endpoint), subject-reported procedural pain (11-point scale), and investigator and subject assessments using the Global Aesthetic Improvement Scale (GAIS). A total of 175 subjects were included. The primary endpoint was met, with response rates of 84.2% for VYC-17.5L and 82.5% for control. Mean pain scores after initial and touch-up treatments were 2.4 for VYC-17.5L versus 5.2 for control ( < 0.001) and 2.0 versus 3.3 ( < 0.001), respectively. Investigator-rated GAIS scores were 86.5% for VYC-17.5L versus 86.0% for control. There were no between-group differences in subject-rated GAIS scores. Safety profiles were comparable for VYC-17.5L and control. VYC-17.5L was noninferior to control without lidocaine for correcting moderate-to-severe NLFs in Chinese subjects and was superior to control in reducing procedural pain.